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A major challenge in developing an HIV-1 vaccine is to identify immunogens and their delivery methods that can elicit broad neutralizing
antibodies against primary isolates of different genetic subtypes. Recently, we demonstrated that priming with DNA vaccines expressing primary
HIV-1 envelope glycoprotein (Env) followed by recombinant Env protein boosting was successful in generating positive neutralizing antibody
responses against a clade B primary HIV-1 isolate, JR-FL, that was not easily neutralized. In the current study, we examined whether the DNA
priming plus recombinant protein boosting approach delivering a polyvalent primary Env formulation was able to generate neutralizing antibodies
against primary HIV-1 viral isolates from various genetic subtypes. New Zealand White rabbits were first immunized with DNA vaccines
expressing one, three or eight primary HIV-1 gp120 antigens delivered by a gene gun followed by recombinant gp120 protein boosting.
Neutralizing antibody responses were examined by two independently executed neutralization assays: the first one was a single round infection
neutralization assay against a panel of 10 primary HIV-1 isolates of subtypes A, B, C and E and the second one used the PhenoSense assay against
a panel of 12 pseudovirues expressing primary HIV-1 Env antigens from subtypes A, B, C, D and E as well as 2 pseudoviruses expressing the Env
antigens from MN and NL4-3 viruses. Rabbit sera immunized with the DNA priming plus protein boosting approach, but not DNA vaccine alone
or Env protein alone, were capable of neutralizing 7 of 10 viruses in the first assay and 12 of 14 viruses in the second assay. More importantly, sera
immunized with the polyvalent Env antigens were able to neutralize a significantly higher percentage of viruses than the sera immunized with the
monovalent antigens. Our results suggest that DNA priming followed by recombinant Env protein boosting can be used to deliver polyvalent Env-
antigen-based HIV-1 vaccines to elicit neutralizing antibody responses against viruses with diverse genetic sequence variations.
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doi:10.1016/j.virol.2006.02.032to be moved into phase III clinical trials. Lately, there has been
notable progress in inducing protective immune responses
based on cell-mediated immune (CMI) responses. By using the
rhesus macaque model, several studies independently estab-
lished protection of monkeys against the chimeric SHIV89.6
challenges (Amara et al., 2001; Barouch et al., 2000; Shiver et
al., 2002) mainly based on the Gag-specific CMI responses.
Fig. 1. Design of animal groups for DNA prime and protein boost immunization
study. New ZealandWhite rabbits received either DNAvaccines (monovalent or
polyvalent components) or plasmid vector control at weeks 0, 4, 8 and 16
followed by two boosts with recombinant gp120 glycoproteins at weeks 40 and
44. The gp120 form of Env antigens was used for both DNA prime and protein
boost. The original sources of viral isolates from which the primary gp120 genes
were cloned are listed at the bottom of the figure.
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long-term viral setting point and avoiding the decline of CD4+
T-cell counts, none was able to induce a sterilizing immunity
which demands an early and complete blocking of viral
infection to the target cells—a task traditionally requiring the
strong anti-viral neutralizing antibody responses (Mascola and
Montefiori, 2003; Morris, 2002). Despite the effort of the last
two decades, there has been little progress toward the goal of
generating broadly neutralizing antibody responses against
HIV-1 through immunization. A frequently cited reason for this
failure was that HIV-1 mutates all the time and the new escaping
viral isolates prevent the development of vaccines based on only
one HIV-1 envelope (Env) antigen (Wei et al., 2003).
There are two approaches to address this challenge. First, it
was hoped that a common neutralizing antigen structure can be
identified on most of the Env proteins from the primary HIV-1
isolates. A number of approaches have been put into this
strategy in the last two decades, such as the principal
neutralizing domain (PND) based on the V3 loop (Javaherian
et al., 1989, 1990), the broadly neutralizing monoclonal
antibodies (Burton et al., 2005; Conley et al., 1994; Moulard
et al., 2002; Muster et al., 1994; Purtscher et al., 1994; Scanlan
et al., 2002; Zwick et al., 2001), induction of fusion
intermediates (LaCasse et al., 1999) and lately the consensus
env gene sequences (Gao et al., 2004; Gaschen et al., 2002). But
so far none has led to the production of one single HIV-1 Env
antigen which is capable of inducing broadly neutralizing
antibody responses against multiple primary viral isolates. The
other approach which has not been fully explored is the use of
polyvalent antigens as vaccines (Hurwitz et al., 2005). A non-
human primate study showed that a polyvalent formulation
consisting of HIV-1 Env antigens was able to induce stronger
neutralizing antibodies and better protection against the
chimeric SHIV viral challenge, but the protection was not
correlated to the neutralizing antibody responses (Cho et al.,
2001). However, the above study only used Env antigen from
clade B viral isolates. The polyvalent approach has not been
well studied by using Env antigens from different clades of
primary HIV-1 isolates circulating in the world.
One of the difficulties to develop polyvalent Env vaccines is
the complex process to screen, select and produce multiple
recombinant Env protein antigens. We have used DNA
immunization as a tool in early stage preclinical studies to test
polyvalent Env formulation. In this approach, multiple DNA
vaccines expressing various primary Env antigens can be
produced inexpensively and delivered easily in one mixture.
The ability of DNA vaccines to elicit anti-Env antibody
responses has been well documented with Env from T-cell-
line-adapted (TCLA) HIV-1 isolates (Lu et al., 1995, 1996,
1998), and levels of anti-Env antibody responses can be further
improved by using recombinant TCLA Env proteins as the
boost (Barnett et al., 1997; Richmond et al., 1998) although
recombinant Env proteins alone have not been very immuno-
genic in inducing strong antibody responses in both animal
studies and human HIV vaccine trials (Ackers et al., 2003).
Recently, we used the DNA prime and protein boost approach
in generating neutralizing antibody responses against JR-FL, aprimary HIV-1 isolate relatively resistant to neutralization
(Wang et al., 2005). The DNA prime and protein boost approach
was also proven effective when a structurally modified JR-FL
Env antigen (Beddows et al., 2005) or V2 domain deleted Env
was used (Barnett et al., 2001).
As a pilot study to test the feasibility of using the DNA prime
and protein boost approach to deliver polyvalent Env vaccines,
here we immunized New Zealand White (NZW) rabbits with
DNA vaccines coding for primary Env antigens followed by
recombinant Env protein boosts, either with single antigen or in
various polyvalent combinations up to eight primary Env
proteins. Data from the current study demonstrated that
polyvalent gp120 DNA immunization was effective in
generating antibody responses against a wide range of primary
HIV-1 Env glycoproteins. Boosting these rabbits with the
recombinant gp120 proteins further improved the titers and
more importantly the neutralizing activities against primary
viral isolates across several major subtypes circulating in the
world. Based on data generated from this “proof-of-principle”
pilot study, the polyvalent Env vaccine formulation delivered by
the DNA prime and protein boost approach offers an attractive
strategy to develop a clinical AIDS vaccine formulation to elicit
neutralizing antibody responses with improved breadth.
Results
Selection and production of HIV-1 gp120 DNA and
recombinant gp120 protein vaccines
In the current study, eight primary HIV-1 envelope
glycoproteins were randomly selected from 7 different subtypes
(clades A to G) of HIV-1 M group. As shown in Fig. 1, this
group of primary viral samples was collected from HIV-1-
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America which include both R5 and X4 phenotypes (Gao et al.,
1996). The gp120 gene inserts were PCR amplified from the
full-length env genes with the high fidelity PFU polymerase and
subcloned into the DNA vaccine vector pSW3891, a vector for
potential human clinical trial use derived from the pJW4303
vector as previously reported (Lu et al., 1999). The ability of
DNA vaccines to express gp120 antigens was confirmed in
transiently transfected 293T cells before being used in animal
study. Four of these primary env genes were further expressed
as recombinant gp120 glycoproteins in stably transfected 293
cells, and the purified gp120 proteins were used for the boost.
Immunization schedule of DNA plus protein formulation
The immunogenicity of primary HIV gp120 DNA vaccines
was studied as either monovalent, 3-valent or 8-valent
combinations in NZW rabbits (Fig. 1). In the DNA priming
phase, each animal received four DNA immunizations by a gene
gun at weeks 0, 4, 8 and 16. The total amount of DNA at each
immunization was fixed at 36 μg, but the dose for each gp120
DNAvaccine varies depending on the number of DNAvaccines
included in the polyvalent formulations. In the 3-valent group,
the dose for each DNA plasmid was 12 μg, while in the 8-valent
group, the dose was 4.5 μg each (Fig. 1). The protein-boosting
phase consisted of two intradermal immunizations of recombi-
nant gp120 mixed with Incomplete Freund Adjuvant (IFA) at
weeks 40 and 44. For the monovalent and 3-valent DNA
groups, the homologous gp120 recombinant proteins were used
as the boost. For the 8-valent DNA group, the protein boost
consisted of 4-valent recombinant gp120 proteins (Fig. 1),
which were homologous to 4 of 8 DNA vaccine components
used during priming phase. The dose of protein boost at each
immunization was fixed at a total amount of 100 μg per
immunization. The control group received 4 times of empty
pSW3891 DNA vector inoculations followed by twice 4-valent
recombinant gp120 protein boosts as described above.
Anti-gp120 IgG responses in rabbit sera after DNA priming
At the end of DNA priming, substantial levels of antibody
responses were induced in both monovalent and polyvalent
gp120 DNA vaccine groups against the primary HIV-1 gp120Fig. 2. HIV-1 gp120-specific IgG responses at the end of DNA priming. (A and
B) Levels of anti-gp120 IgG were measured by ELISA for rabbits sera
immunized with either the monovalent DNAvaccines expressing one of the four
primary gp120 antigens (A) or the polyvalent DNA vaccines expressing 3 or
8 primary gp120 antigens (B). The DNA vaccines used are marked at the right
upper corner of each panel. The arrows indicate where the homologous gp120
were used as the coating antigens. Geometric means of the anti-gp120 IgG titers
against each particular gp120 antigen are shown with standard deviations. The
mean serum titers from polyvalent rabbits were marked by the horizontal lines.
The difference between 3-valent and 8-valent was statistically significant based
on the Student's t test (p < 0.02). (C) Specificity of rabbit anti-gp120 IgG
analyzed by the Western blot. Equal amounts of secreted gp120 antigens (10 ng)
from transiently transfected 293T cells were loaded onto each lane of SDS-
PAGE. Rabbit sera collected 2 weeks after the fourth DNA immunization were
used at a dilution of 1:500.antigens as measured by ELISA. The overall immunogenicity
of 4 individual gp120 DNAvaccines (B, Bal, C and E) was very
similar. The anti-gp120 IgG titers reached ∼1:100,000 even
though the rabbit sera usually recognized the homologous
gp120 antigen slightly better (indicated by an arrow in Fig. 2A)
37S. Wang et al. / Virology 350 (2006) 34–47than the other primary gp120 antigens, except the DNAvaccine
expressing C gp120 antigen. For rabbits which received 3-
valent DNAvaccines, the preferred recognition for homologous
gp120 antigen disappeared. Similarly, the rabbit sera from the 8-Fig. 3. Improvement of anti-gp120 IgG responses after protein boosts in rabbits prim
were collected prior to the DNA immunizations (Pre-bleed), 2 weeks after the fourt
second (Protein-II) protein boost immunizations. Four recombinant gp120 proteins (
design in Fig. 1). (A) Sera from rabbits immunized with the monovalent DNA plus pro
plus protein gp120 vaccines. (C) Sera from rabbits received empty vector DNA follvalent DNA vaccine group also had comparable reactivity
against most of the eight primary gp120 antigens. It was
interesting to observe that the mean titer of 3-valent DNA
vaccine group was higher than that from the 8-valent DNAed with various DNA vaccine formulations as analyzed by ELISA. Rabbit sera
h DNA immunization (DNA-prime), 2 weeks after the first (Protein-I) and the
B, C, E and Bal) were used, either alone or in combinations, for the boost (see
tein gp120 vaccines. (B) Sera from rabbits immunized with the polyvalent DNA
owed by protein boosts (as shown in Fig. 1).
Table 1
Neutralization activities against HIV-1 primary isolates from clades A, B, C and E
Rabbit sera used at 1:5 dilution were collected at 2 weeks after the fourth DNA immunization (Post-DNA), 2 weeks after the first protein boost (Protein-I) and 2
weeks after the second protein boost (Protein-II). Virus neutralization assays were performed using a single round of infection with flow cytometry measurement
of intracellular HIV-1 p24-Ag in HIV-1-infected T cells. The percent neutralization of each rabbit serum was calculated by the reduction in the number of p24-
Ag positive cells in the test wells with immune sera, compared to the number of p24-Ag positive cells in wells containing pre-immune sera. To quantify the p24
positive PBMC, background events in mock-infected cells were subtracted. Each immune rabbit serum was compared to their pre-immune sera. “–” indicates that
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39S. Wang et al. / Virology 350 (2006) 34–47vaccine group (p < 0.02) (Fig. 2B) although the frequency of
immunizations and the total amount of DNA vaccines at each
immunization were the same for both groups. The higher titer of
gp120-specific antibody in 3-valent immunized rabbit sera was
further confirmed by Western blot analysis that the 3-valent sera
had stronger and broader reactivity against primary gp120
antigens than the 8-valent sera (Fig. 2C).
Anti-gp120 IgG responses after protein boost
DNA immunized rabbits were further boosted with two
protein immunizations. For the monovalent group, there was a
quick elevation of anti-gp120 IgG responses after only one
protein boost as measured by ELISA (Fig. 3A). The anti-gp120
titers did not improve significantly with the second protein
boost, suggesting that one protein immunization was sufficient
to boost the anti-gp120 antibody titer to the peak levels in these
animals. Similarly, for 3-valent group, one protein immuniza-
tion boosted the anti-gp120 IgG response close to their peak
levels against each of the three primary gp120 antigens included
in the DNA prime and protein boost. The effects of the second
protein boost were minimal (Fig. 3B).
Anti-gp120 antibody responses in rabbits immunized with
the 8-valent DNA formulation showed a very different pattern
and increased with each of the two protein boosts (Fig. 3B). One
protein boost was effective in improving the anti-gp120 IgG
titers, but the levels were clearly lower than that achieved after
the second protein boost. Because the anti-Env IgG titers at the
end of DNA priming were already lower in the 8-valent DNA
group than that in the 3-valent DNA group (Fig. 2B), the aboveTable 2
Neutralizing antibody titers against HIV-1 pseudoviruses in immunized rabbit sera a
Animal
Groups
Clade B Clade
MN SF162 NL4-3 92BR020 92US715 JRCSF 93IN905 98
Monovalent group
R-A01 5500 14672 785 605 – – – –
R-A02 4808 10133 1740 108 – – – –
R-B01 6093 38738 2104 461 164 – 33 3
R-B02 7278 49605 251 593 226 – – –
R-C01 701 53026 26 211 73 – 106 6
R-C02 978 33272 55 198 67 – 102 7
R-D01 166 27451 – 150 – – – –
R-D02 103 21555 – 54 – – 90 –
Polyvalent group
R-E01 2038 59842 755 415 124 – 110 8
R-E02 28048 76117 192 285 100 – 52 5
R-F01 32340 64632 207 225 66 – 33 7
R-F02 1315 29411 231 285 71 – – 6
Protein alone group
R-G01 976 11641 – 91 – – – –
R-G02 – 994 – – – – 16 –
Control antibodies
N16 3975 7730 2042 150 143 421 111 18
Pre-bleed – – – – – – – –
“–” indicates that the neutralizing activities were below 50% inhibition at 1:15 seru
a Sera at the peak level anti-gp120 antibody responses (2 weeks after the seconddata would suggest that one protein boost was not sufficient for
the 8-valent DNA group to achieve the antibody responses to
the same plateau level as the 3-valent DNA group after one
protein boost. Protein boosts alone in control animals without
gp120 DNA vaccine priming were unable to elicit high level of
anti-gp120 IgG responses (Fig. 2C).
Neutralization against primary HIV-1 viral isolates using a
single round infection assay system
Neutralization activities of the above rabbit sera elicited by
the DNA prime and protein boost approach were analyzed
independently by two different neutralization assays. The first
one was conducted against a panel of 10 primary HIV-1 isolates
(Table 1), using a flow-cytometry-based single-round infection
system to detect HIV-1-infected T cells by intracellular staining
for HIV-1 p24 (Mascola et al., 2002). This assay directly
compares pre-immune and post-immune rabbit sera, a value of
50% neutralization or above is clearly positive and reproducible
(Mascola et al., 2002). At the end of DNA priming, no
significant neutralizing activity was detected except that against
HIV-1 isolate SF162, a virus that is sensitive to neutralization.
After only one protein boost, however, we detected positive
neutralizing activities against multiple primary viruses, includ-
ing SF162, Bal, JRCSF (clade B), TV1 (clade C) and DJ263
(clade A). After the second protein boost, more sera showed
positive neutralizing activities, including those that attained
higher strength (>75%, shown in orange shaded areas) and
those against additional primary isolates such as S007 and
DU151 (clade C) (Table 1). The negative control rabbit seraC Clade A Clade D Clade E
CN006 92RW020 94UG103 92UG046 94UG114 92TH021 CMU02
– – – – – –
– – – – – –
8 – – – – – –
– – – – – –
8 – – – – – –
2 65 23 – – – –
– – – – – –
– – – – – –
2 65 – – 33 16 –
4 53 – – – – 20
5 34 16 – 30 17 15
7 45 – – – – –
– – – – – –
– – – – – –
3 74 65 69 95 80 124
– – – – – –
m dilution.
protein boost) were used in this assay. The starting serum dilution was 1:15.
40 S. Wang et al. / Virology 350 (2006) 34–47(G01 and G02), which received the empty DNA vector as
prime, showed no significant neutralizing activities even after
two gp120 protein boosts.
We used two broadly neutralizing monoclonal antibodies
(mAb), 2F5 and 2G12, and the pooled human immunoglobulin
from HIV-infected patients (HIVIG) as positive controls.
Although 2F5 and 2G12 demonstrated consistent neutralizing
activities at 50 μg/ml, they could not neutralize several primary
viral isolates, producing a pattern very similar to that of rabbit
sera elicited by our DNA prime plus protein boost approach
(Table 1). Whereas 2F5 had positive neutralizing activities
against two clade E viral isolates, 2G12 had weaker and
narrower neutralizing activities than several rabbit sera. At a
reduced concentration (5 μg/ml), both mAbs showed much
weaker neutralizing activities. As learned from recent report,
these two mAbs may not be effective against clade C viruses
(Binley et al., 2004).
HIVIG at 10 mg/ml had broad and strong neutralizing
activities, but at 1 mg/ml, its activities reduced to a level similar
to that of rabbit sera induced by the DNA prime plus protein
boost immunization approach (Table 1). The total normal
human blood IgG level is 8 to 15 mg/ml, so purified HIVIG, at
10 mg/ml of IgG, equals undiluted human sera. The range of
total IgG in our rabbit immune sera was 15–25 mg/ml, and the
average of gp120-specific IgG was at 200 μg/ml after two
protein boosts. At 1:5 sera dilution, total IgG in rabbit sera
would be at 3–5 mg/ml and gp120-specific IgG at 40 μg/ml.Fig. 4. The frequencies of neutralization against the pseudotyped viruses expressing p
protein boost (a), polyvalent DNA prime/protein boost (b) and polyvalent protein alo
were able to neutralize pseudoviruses included in this assay. The open area in the pie c
the neutralization frequencies against all 14 HIV-1 pseudoviruses; the middle row sho
bottom row shows the neutralization frequencies against 8 HIV-1 pseudoviruses from
shown at the right for each pair of groups. (a) vs. (b): between monovalent (a) and poly
(b) and protein alone (c) groups. The range and average titers of neutralizing activitNeutralization against primary HIV-1 viral isolates using a
pseudotyped virus system
The second neutralization assay was conducted by using a
PhenoSense assay system (Richman et al., 2003) against a panel
of 12 pseudotyped viruses expressing primary HIV-1 Env
antigens. Two T-cell-line-adapted (TCLA) HIV-1 viruses (MN
and NL4-3) were also included. In this assay, the levels of
neutralizing activities in rabbit immune sera were quantitatively
determined by the end titration titers that were able to generate
>50% neutralization.
Based on the results learned from the first neutralization
assay, we only included the rabbit sera after the second protein
boost for this pseudovirus-based assay. Rabbit sera immunized
with DNA prime and protein boost approach had overall high
levels of neutralizing antibody responses (Table 2). Their titers
against MN and SF162 were even better than the positive
control HIV patient sera N16 that was used in a recent report
with proven high level neutralizing antibody activities against
a wide range of primary HIV-1 isolates (Binley et al., 2004).
The DNA prime plus protein boost approach also elicited
various levels of neutralizing antibodies against NL4-3 and 9
other viruses which express primary HIV-1 Env antigens from
clade A (92RW020 and 94UG103), clade B (92BR020 and
92US715), clade C (93IN905 and 98CN006), clade D
(94UG114) and clade E (92TH021 and CMU02). These viruses
were more resistant to neutralization since the positive controlrimary HIV-1 antigens by rabbit sera immunized with monovalent DNA prime/
ne (c). The gray areas in the pie charts indicated the frequency for rabbit sera that
harts showed the frequency that such sera failed to neutralize. The top row shows
ws the neutralization frequencies against 6 HIV-1 clade B pseudoviruses; and the
clades A, C, D and E. The p values of statistic analysis by Chi-square test are
valent DNA/protein groups (b), and (b) vs. (c): between polyvalent DNA/protein
ies against clade B or clades A, C, D and E viruses were marked.
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that against SF162 (Table 2). The neutralizing antibody titers in
rabbit immune sera were comparable or close to that of N16
against the clades A, B and C primary Env antigens, but lower
than N16 against clades D and E primary Env antigens. Two
viruses, one from clade B (JRCSF) and one from clade D
(92UG046), were not neutralized by any of the rabbit immune
sera. The control rabbit sera which received protein alone
immunizations had only meaningful neutralizing antibodies
against MN and SF162 but occasional neutralizing activities
against 2 other primary viruses (Table 2).
Further analysis on the breadth of neutralizing activities
revealed clear advantage of the polyvalent Env formulations
(Fig. 4). The frequencies of positive neutralization by
monovalent or polyvalent formulations were calculated as the
percent of positive neutralization events as part of the total
neutralization events against either clade B, non-clade B or all
14 HIV-1 pseudoviruses. The frequencies of positive neutral-
ization against these HIV-1 pseudoviruses were significantly
different between the monovalent and polyvalent groups. The
frequency for polyvalent sera to neutralize all 14 viruses
included in the assay was 67.86%, while the frequency for
monovalent sera was 38.39% (p < 0.001). When clade B and
non-clade B viruses were analyzed separately, the polyvalent
sera have a neutralization frequency of 56.25% against the
8 viruses from clades A, C, D and E as compared to the
monovalent group that only had a frequency of 14.06% against
the same set of non-clade B viruses (p < 0.001). Protein
immunizations alone sera were clearly less capable in
generating broad neutralizing antibody responses (Fig. 4). The
overall titers against non-clade B viruses were lower than that
against clade B viruses as indicated at the bottom of Fig. 4.
Discussion
The important role of the neutralizing antibody in HIV
vaccine development has been supported by many studies
including the protection of non-human primates with passive
transfer of neutralizing monoclonal antibodies (Mascola, 2002;
Mascola et al., 1999, 2000; Nishimura et al., 2002, 2003;
Ruprecht et al., 2001, 2003; Shibata et al., 1999; Xu et al.,
2002). Broadly neutralizing antibodies have been demonstrated
in some of the HIV-infected patients (Bures et al., 2002; Pilgrim
et al., 1997), but the production of such antibody in infected
patients seems always one step behind their escape mutants
(Wei et al., 2003). However, for a prophylactic HIV vaccine, it
is still a desired scenario to induce broad neutralizing antibodies
in a high-risk population before being infected with HIV
because such broad humoral immunity is important to prevent
the invading virus from establishing a persistent infection.
There are a number of obstacles to the development of HIV-1
vaccines that are capable of inducing broad neutralizing
antibody responses. The first is the poor immunogenicity of
Env proteins. Recombinant HIV-1 envelope protein-based HIV
vaccines were unable to elicit high level antibody responses in a
number of early human clinical studies (Belshe et al., 1993;
Keefer et al., 1994; Salmon-Ceron et al., 1995; Valentine et al.,1996). In recently published phase III HIV vaccine trial reports,
the antibody responses remained suboptimal, although volun-
teers had received 7 immunizations of recombinant gp120
proteins (Gilbert et al., 2005a, 2005b). The mechanism for such
a poor immunogenicity is not well studied, but it was
hypothesized that the heavy glycosylation and complicated
oligomer structure may have contributed to such phenomenon
(Moore and Burton, 2004).
The second major obstacle is the high mutation rate in HIV
which makes it difficult for any candidate HIV vaccines
targeting at only one particular Env antigen. Previous attempts
to develop vaccine candidates based on fusion intermediates
(LaCasse et al., 1999) or specific epitopes modeled after the
monoclonal antibodies (Labrijn et al., 2003; Liang et al., 1999;
McGaughey et al., 2003; Zwick et al., 2003) have not had much
success. The more recent strategies of using consensus or
ancestor sequences based on computer analysis of HIV gene
sequences have not shown broadly neutralizing antibodies, even
though the cross reactivity of immune sera against selected HIV
envelope antigens may have been improved (Gaschen et al.,
2002).
The current pilot study is part of our continued effort to
address these two major obstacles with a different approach.
Over the last decade, the DNA immunization technology has
been widely accepted as a tool to induce cell-mediated immune
responses. However, our previous studies have also suggested
that DNA immunization is equally powerful in inducing high
level antibody responses against HIV antigens in both small
animal and non-human primate models including neutralizing
antibodies against primary SIV virus (Lu et al., 1995, 1996).
DNA immunization offers a unique advantage to further modify
the envelope antigens to make them more immunogenic
(Barnett et al., 2001; Lu et al., 1998). More importantly, it
was shown that the levels of neutralizing antibodies are
improved when recombinant HIV envelope proteins are given
as a boost to animals already primed with the DNA vaccines
expressing the HIV envelope antigens (Richmond et al., 1998).
Such DNA prime plus protein boost approach was also effective
in a non-human primate study (Letvin et al., 1997), although
mainly the HIV-1 TCLA viral isolate antigens were used in the
above studies. Recently, we demonstrated that the DNA prime
plus protein boost approach was effective in eliciting neutral-
izing antibody response against JR-FL, a viral isolate relatively
difficult to be neutralized (Wang et al., 2005).
In the current study, we further tested whether multiple
primary HIV envelope antigens can be administered with the
DNA prime plus recombinant protein boost approach. Our data
confirmed that polyvalent DNA formulation alone was already
effective in inducing strong binding antibody responses against
a wide range of primary Env antigens, although such immune
sera were not able to neutralize most of the primary HIV-1
viruses. With only one protein boost, positive neutralizing
activities against primary HIV viral isolates were clearly
detected. A second protein boost was able to increase both the
titer and breadth of neutralizing antibody responses against a
wide range of primary isolates from different clades. Thus, our
data provided important evidence that the DNA prime plus
42 S. Wang et al. / Virology 350 (2006) 34–47protein boost vaccine strategy is effective in delivering
polyvalent, primary Env-based HIV vaccine formulations to
elicit neutralizing activities with improved breadth.
It was also interesting to observe that both monovalent and 3-
valent DNAvaccine formulations were more immunogenic than
the 8-valent formulation at the priming phase. Such difference
also affected the numbers of protein boosts required to reach the
peak level antibody response. It is possible that the 8-valent
DNA group with reduced dose for each DNA vaccine
component may have led to the reduced antibody responses
due to the dilution effect to the immunogens. However, even
sera from the monovalent and 3-valent groups could at least
partially recognize heterologous primary gp120 antigens.
Therefore, the exact mechanism may be more complicated. It
may also suggest the existence of limitation on clonal expansion
of memory B cell populations. When a large numbers of
antigens with similar structures are delivered, there may be a
competition in the simultaneous expansion of these clones so
the total antibody responses may be lower than when less
numbers of antigens are delivered at the same time. Further
studies on the above mechanisms are needed because they will
guide the ultimate decision on what will be the optimal numbers
of Env antigens to be incorporated in a polyvalent Env vaccine
formulation.
We noticed that, for the monovalent and 3-valent formula-
tions, the breadth of neutralizing activities increased further
after the second protein boost, but the ELISA titers did not
(Table 1 and Fig. 3). The exact mechanism of this phenomenon
is not clear. It is possible that the second protein boost might
further improve the antibody responses against carbohydrate or
other conformational epitopes primed by DNA vaccines, which
were not reflected in the ELISA-based binding antibody assay.
It is also possible that the second protein boost might lead to
better antibody maturation with increased antibody avidity as
we recently reported (Wang et al., 2005) which may further
improve the quality of neutralizing activity.
Our data also demonstrated similar utility for two different
types of neutralization assays. Overall, the flow-based neutral-
ization was more stringent to give high titers and thus a high
percentage inhibition (>75%) would represent meaningful
neutralizing activities even at low sera dilutions (Mascola et
al., 2005). A unique finding was that HIV-1 isolate JFCSF was
neutralized in flow-based assay but not neutralized in the
pseudotyped virus assay (Tables 1 and 2). There are several
possibilities. First, the target cells used in these two assays were
different. Second, the serum dilution may also be partially
responsible (1:5 in flow-based assay and 1:15 in pseudotyped
virus assay).
The polyvalent formulations included in this pilot study were
selected purely based on the available primary Env antigens at
the time when we started this study several years ago. While
they represented different genetic clades, early studies demon-
strated that the neutralizing antibody responses did not follow
the genetic sequences of primary antigens (Moore et al., 1996),
but recent studies also suggested a weak correlation between
serum neutralization and the genetic clade (Binley et al., 2004).
Our finding that polyvalent formulations were more effective ingenerating broader neutralizing antibody responses than
monovalent Env formulations will open a door for more such
studies. For example, we need to know whether certain primary
Env antigens will be more effective than others in inducing
broad neutralizing antibody responses. Such Env antigens will
be better candidates for polyvalent Env formulations than
randomly selected Env antigens. Based on the results of these
studies, additional polyvalent formulations with completely
different set of primary Env antigens will be tested to see
whether the breadth of neutralizing antibodies shown in the
current study can be further improved because in current study
there were still viruses that were completely resistant to the
rabbit immune sera.
In addition, the ability of DNA prime and protein boost
approach to elicit neutralizing antibodies through immunization
will allow further studies to map the critical neutralizing
epitopes which was not included in the current pilot study. For
polyvalent Env formulations, it is even more important to know
whether the breadth of neutralizing antibodies is dependent on
more positive neutralizing epitopes or against several versions
of the major epitopes, e.g. the V3 epitope of Env proteins from
different genetic clades.
We also need to expand the size of animal groups to
determine whether the 3-valent and 8-valent formulations are
equally effective in eliciting the same breadth of neutralizing
antibody responses. The most important questions, of course,
would be whether the same DNA prime plus protein boost
approach can generate broad neutralizing antibody responses in
human studies. Nevertheless, results presented in this pilot
study provided a technical platform to allow us to develop more
effective HIV vaccines by using polyvalent Env formulations.
Materials and methods
DNA vaccines
The HIV env gene clones coding for A-120, B-120, C-120,
D-120, E-120, F-120 and G-120 were received from Drs. Feng
Gao and Betrice Hahn, University of Alabama at Birmingham.
The gene coding for Bal-120 was prepared under contract with
the National Institute of Allergy and Infectious Diseases
(NIAID) in collaboration with the Institute of Human Virology.
The DNA vaccine inserts coding for the above eight primary
gp120 antigens were first PCR amplified by using PFU
polymerase (Stratagene, La Jolla, CA) and subcloned into the
DNA vaccine vector pSW3891. A pair of consensus PCR
primers were designed and used to amplify eight different
gp120 genes: the plus strand primer GP120-p-f1 (p-cttgtgggtca-
cagtctattatggggtacc) and the minus strand primer GP120-p-b1
(ggtcggatccttactccaccactcttctctttgcc). The pSW3891 was de-
rived from pJW4303 (Lu et al., 1999) with the following
modifications: the SV40 origin sequence was deleted and the
Ampicillin resistance gene was replaced by the Kanamycin
resistance gene. The pSW3891 contains the CMV immediate
early (IE) promoter and its associated Intron A sequence. The
HIV-1 gp120 inserts were fused in frame with a tissue
plasminogen activator (tPA) leader sequence. The gp120
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prepared by using the Giga-plasmid purification kit (Qiagen,
Valencia, CA) after their expressions were first confirmed by
Western blot analysis using transiently expressed gp120 from
293T cells.
Protein vaccines
The recombinant gp120 proteins (B, Bal, C and E) were
expressed in stably transfected 293 cells under the control of
CMV promoter. The gp120 genes were cloned in frame with the
tPA signal peptide to achieve secretion of the protein into the
medium. The gp120 expression vector also contains neomycin
phosphotransferase (neo) gene for the selection of stable HIV-1
gp120 expressing 293 cells in the presence of the drug
Geneticin (G418 sulfate). Cell lines stably transfected with
gp120 env genes were adapted to grow in serum-free medium.
Secreted gp120 protein from the conditioned medium was
purified by either Galanthus nivalis lectin or immunoaffinity
chromatography with an anti-gp120 monoclonal antibody
directed towards a conformational epitope on the glycoprotein
(unpublished results).
Immunization
Female New ZealandWhite (NZW) rabbits of 6–8 weeks old
(∼2 kg of body weight) were purchased from Millbrook Farm
(Amherst, MA) and housed in the animal facility managed by
the Department of Animal Medicine at the University of
Massachusetts Medical School in accordance with IACUC
approved protocol. Groups of rabbits first received four DNA
immunizations at weeks 0, 4, 8 and 16 by a Bio-Rad Helios
gene gun (Bio-Rad, Hercules, CA). The gp120 DNA vaccine
plasmids or the negative control pSW3891 vector plasmid were
coated on to the 1.0 μm gold beads at a ratio of 2 μg of DNA per
mg of gold. Each gene gun shot delivered 1 μg of DNA and a
total of 36 non-overlapping shots were delivered to each rabbit
on shaved abdominal skin at each immunization. The animals
then received two monthly recombinant gp120 protein boosts at
weeks 40 and 44. A total of 100 μg recombinant gp120 proteins
was administered intradermally with Incomplete Freund's
Adjuvant (IFA, Sigma, St. Louis, MO) at each protein
immunization. The serum samples were collected immediately
before and 2 weeks after each immunization.
In vitro expression of gp120 antigens by DNA vaccines
The expression of primary gp120 antigens from DNA
vaccine plasmids was conducted in transiently transfected 293T
cells (Numa et al., 1995; Pear et al., 1993). The 293T cells were
grown in Dulbecco's Modified Eagle Media (DMEM, Invitro-
gen) supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 100 μg/ml of streptomycin and 100 IU/ml
penicillin. Each of the 60-mm tissue culture dishes (2.5 × 106
cells) was transfected with 10 μg of individual gp120 DNA
vaccine plasmid or the empty pSW3891 vector by calcium
phosphate precipitation (Batard et al., 2001). The supernatantswere harvested 72 h post-transfection, and the gp120 proteins
were then used for ELISA or Western blot analysis. The
concentration of each gp120 antigen was determined by a
quantitative ELISA using the recombinant gp120 protein with
known concentration as the standard.
Enzyme-linked immunosorbent assay (ELISA)
Rabbit sera were tested for gp120-specific IgG antibody
responses by ELISA. 96-well microtiter plates (Corning, NY)
were first incubated with ConA (5 μg per well in 100 μl of PBS,
pH 7.2) for 1 h then coated with 100 μl of gp120 antigens (1 μg/
ml) from transiently transfected 293T cell supernatant. After
wells were blocked with 200 μl/well of blocking buffer (4%
milk-whey in PBS) for 1 h, 100 μl of serially diluted rabbit sera
was added in duplicate wells and incubated for 1 h. Following
the antibody incubation, 100 μl of biotinylated anti-rabbit IgG
(Vector Laboratories, Burlingame, CA) at 1:1000 dilution was
added to each well and incubated for 1 h, horseradish-
peroxidase (HRP)-conjugated streptavidin (Vector Laborato-
ries) at 1:2000 dilution was then added (100 μl/well) and
incubated for 1 h. Between each step, the plates were washed 5
times with washing buffer (PBS at pH 7.2 with 0.1% Triton X-
100). Finally, 100 μl/well of fresh TMB substrate (Sigma) was
added and incubated for 3.5 min. The reaction was stopped by
adding 50 μl of 2 N H2SO4. The absorptance was measured at
the optical density (OD) of 450 nm (OD450). The end titration
titer was determined when the OD450 value at the greatest serum
dilution was 2-fold higher than the OD450 value of the negative
control wells with the normal rabbit sera. The difference
between certain sets of anti-gp120 IgG titers was further
analyzed for statistical significance by the Student's t test.
Western blot analysis
The gp120 antigens (10 ng/lane) in supernatants from
transiently transfected 293T cells were subjected to SDS-PAGE
and blotted onto PVDF membrane. Blocking was done with
0.1% I-Block (Tropix, Bedford, MA). The membranes were
incubated with immunized rabbit sera at 1:500 dilution for
45 min and subsequently reacted with AP-conjugated goat anti-
rabbit IgG at 1:5000 dilution for 30 min. Membranes were
washed with blocking buffer after each step. Western-light
substrate was then applied to the membranes for 5 min. Once
the membranes were dried, X-ray films were exposed to the
membrane and developed by a Kodak processor.
Neutralization assays
The first virus neutralization assay was performed using a
single round of infection flow cytometric assay, as previously
described (Mascola et al., 2002). This assay detects HIV-1-
infected T cells by intracellular staining for HIV-1 p24-Ag. A
protease inhibitor is used to prevent secondary rounds of virus
replication (Mascola et al., 2002). Briefly, 40 μl/well of HIV-1
virus stock (multiplicity of infection ∼0.1) was incubated with
10 μl of heat inactivated rabbit serum, or control antibody, for
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were defined at this step. After the incubation, 20 μl of mitogen
stimulated CD4+ T cells (1.5 × 105 cells) was added to each
well. Cells were maintained in IL-2 culture medium containing
1 μM indinavir, and the cells were fed on day 1 with 150 μl of
IL-2 culture medium containing indinavir. T cells were
harvested for intracellular p24-Ag staining on day 2. The cells
were transferred to V-bottom plates and washed once with
phosphate-buffered saline (PBS) containing 1% FBS. Then,
cells were fixed and permeabilized using the Cytofix/Cytoperm
Kit (BD-PharMingen, San Diego, CA) followed by two washes
using the washing buffer provided by the manufacturer. The
permeabilized cells were stained for 20 min at 4 °C with 50 μl of
a phtcoerythrin (PE)-conjugated mouse anti-p24 mAb (KC57-
RD1, Beckman Coulter, Inc., Fullerton, CA). After two
additional washes, the HIV-1- or mock-infected cells were
analyzed with a FACS Calibur flow cytometer (Becton
Dickinson, Franklin Lake, NJ) and the data analysis was
performed with FlowJo software (Tree Star Inc., Ashland, OR).
Live cells initially gated by forward and side scatter were
analyzed for p24 positive cells. After forward and side scatter
gating, 50,000 events were counted. Final quantitation of p24
positive PBMC was done by subtraction of background events
in mock-infected cells. For each rabbit serum, the percent
neutralization was derived by calculating the reduction in the
number of p24-Ag positive cells in the test wells with immune
sera, compared to the number of p24-Ag positive cells in wells
containing pre-immune sera. In each case, the immune rabbit
sera were compared directly to the pre-immune sera from the
corresponding animal. All assays included additional control
wells with a commercial pooled normal rabbit sera (Gemini
Bio-Products, Woodland, CA), as well as positive control wells
containing well-characterized monoclonal or polyclonal neu-
tralizing antibodies (described below). Standard operating
procedures prescribed the acceptable positive and negative
control values, and all data shown are from assays that met these
criteria. Using this assay format that directly compares pre-
immune and post-immune rabbit sera (here done at a serum
dilution of 1:5), we consider values of 50% neutralization to be
clearly positive and reproducible.
The second neutralization assay (PhenoSense Assay) used
recombinant viruses pseudotyped with virus envelope proteins
being tested. Pseudovirus were harvested 48 h after co-
transfecting HEK293 cells with pCXAS-env libraries plus an
HIV genomic vector that contains a firefly luciferase indicator
gene (Richman et al., 2003). Then, they were incubated for 1 h
at 37 °C with serial 4-fold dilutions of heat-inactivated rabbit
sera. U87 cells that express CD4 plus the CCR5 and CXCR4
coreceptors were inoculated with virus dilutions in the absence
of added cations. Virus infectivity was determined 72 h
postinoculation by measuring the amount of luciferase activity
expressed in infected cells. Neutralizing activity is calculated as
the percent inhibition of viral replication (luciferase activity) at
each antibody dilution compared with an antibody-negative
control: % inhibition = {1 − [luciferase + Ab/luciferase −
Ab]} × 100. Titers were presented as the reciprocal of the
plasma dilution conferring 50% inhibition (IC50) (Richman etal., 2003). Statistical analysis with Chi-square test method was
used to analyze the differences between different groups of
rabbit sera.
HIV-1 viruses
HIV-1 primary isolates, and the T-cell-line-adapted HIV-
MN (Doranz et al., 1999; Zolla-Pazner et al., 1998), were
obtained from NIH AIDS Research and Reference Reagent
Program. HIV-1 strains ADA, SF162, Bal and JRCSF are
clade B and well-characterized macrophage-tropic viruses
using CCR5 as coreceptor (Baba et al., 2000; Dragic et al.,
1998; Stauber et al., 1999; Zhang et al., 1999). DU151 and
S007 are clade C viruses that have been previously described
(Bures et al., 2002). TV1 (clade C) was provided by David
Montefiori (Duke University) and Estrelita Janse Van
Rensburg (University of Stellenbosch, South Africa). CM235
and CM244 are clade E viruses, which are macrophage-tropic
and use CCR5 coreceptor (Baba et al., 2000; Baik et al., 1999;
Subbarao et al., 2000). DJ263 is a clade A virus. CM235,
CM244 and DJ263 were provided by investigators from the
U.S. Military HIV Research Program. All primary viral stocks
were prepared and titrated in PHA and IL-2 stimulated human
peripheral blood mononuclear cells (PBMC).
Other viruses used in PhenoSense Assay were pseudovirus
developed to measure antiretroviral drug resistance during a
single round of virus replication and adapted to measure virus–
antibody neutralization (Petropoulos et al., 2000). HIV genomic
RNA was isolated from virus stocks or plasma, and Env PCR
products were cloned into the pCXAS expression vector and
transformed into competent E. coli (Invitrogen). Pseudovirus
particles were produced by cotransfecting HEK293 cells with
pCXAS-env libraries plus an HIV genomic vector that contains
a firefly luciferase indicator gene (Richman et al., 2003). The
list of pseudovirus used in the assay was: clade A (92RW020
and 94UG103), clade B (92BR020, 92US715, MN, SF162,
NL4-3 and JRCSF), clade C (93IN905 and 98CN006), clade D
(92UG046 and 94UG114) and clade E (92TH021 and CMU02).
HIVIG and monoclonal antibodies (mAbs)
Anti-HIV-1 human mAb 2G12 recognizes a carbohydrate-
dependent, conformationally sensitive region of gp120 outside
the CD4 binding site (Trkola et al., 1996). Human mAb 2F5
binds to a linear epitope in the extracellular region of gp41
(Conley et al., 1994; Purtscher et al., 1996). Both mAbs were
kindly provided by Hermann Katinger (Vienna, Austria).
HIVIG is purified IgG from pooled HIV-1 seropositive plasma
which was collected from multiple donors (Lambert et al.,
1997).
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